Intracardiac Hemostasis and Fibrinolysis Parameters in Patients with Atrial Fibrillation

Noémi Klára Tóth, Zoltán Csanádi, Orsolya Hajas, Alexandra Kiss, Edina Nagy-Baló, Kitti Bernadett Kovács, Ferenc Sarkady, L. Muszbek, Z. Bereczky, L. Csiba, Z. Bagoly

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aims. To identify intracardiac hemostasis or fibrinolysis abnormalities, which are associated with atrial fibrillation (AF) and increase the risk of thromboembolism. Patients and Methods. Patient group consisted of 24 patients with AF and control group included 14 individuals with other supraventricular tachycardia undergoing transcatheter radiofrequency ablation. Blood samples were drawn from the femoral vein (FV), left atrium (LA), and left atrial appendage (LAA) before the ablation procedure. Fibrinogen, factor VIII (FVIII) and factor XIII activity, von Willebrand factor (VWF) antigen, thrombin-antithrombin (TAT) complex, quantitative fibrin monomer (FM), plasminogen, α2-plasmin inhibitor, plasmin-α2-antiplasmin (PAP) complex, PAI-1 activity, and D-dimer were measured from all samples. Results. Levels of FVIII and VWF were significantly elevated in the FV and LA of AF patients as compared to controls. TAT complex, FM, PAP complex, and D-dimer levels were significantly elevated in the LA as compared to FV samples in case of both groups, indicating a temporary thrombotic risk associated with the catheterization procedure. Conclusions. None of the investigated hemostasis or fibrinolysis parameters showed significant intracardiac alterations in AF patients as compared to non-AF controls. AF patients have elevated FVIII and VWF levels, most likely due to endothelial damage, presenting at both intracardiac and systemic level.

Original languageEnglish
Article number3678017
JournalBioMed Research International
Volume2017
DOIs
Publication statusPublished - Jun 21 2017

Fingerprint

Antifibrinolytic Agents
Fibrinolysis
Hemostasis
Atrial Fibrillation
Fibrinolysin
Ablation
Femoral Vein
Heart Atria
Factor XIII
Plasminogen
Plasminogen Activator Inhibitor 1
Factor VIII
von Willebrand Factor
Fibrinogen
Blood
Antigens
Atrial Appendage
Supraventricular Tachycardia
Thromboembolism
Catheterization

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Intracardiac Hemostasis and Fibrinolysis Parameters in Patients with Atrial Fibrillation. / Tóth, Noémi Klára; Csanádi, Zoltán; Hajas, Orsolya; Kiss, Alexandra; Nagy-Baló, Edina; Kovács, Kitti Bernadett; Sarkady, Ferenc; Muszbek, L.; Bereczky, Z.; Csiba, L.; Bagoly, Z.

In: BioMed Research International, Vol. 2017, 3678017, 21.06.2017.

Research output: Contribution to journalArticle

Tóth NK, Csanádi Z, Hajas O, Kiss A, Nagy-Baló E, Kovács KB et al. Intracardiac Hemostasis and Fibrinolysis Parameters in Patients with Atrial Fibrillation. BioMed Research International. 2017 Jun 21;2017. 3678017. https://doi.org/10.1155/2017/3678017
Tóth, Noémi Klára ; Csanádi, Zoltán ; Hajas, Orsolya ; Kiss, Alexandra ; Nagy-Baló, Edina ; Kovács, Kitti Bernadett ; Sarkady, Ferenc ; Muszbek, L. ; Bereczky, Z. ; Csiba, L. ; Bagoly, Z. / Intracardiac Hemostasis and Fibrinolysis Parameters in Patients with Atrial Fibrillation. In: BioMed Research International. 2017 ; Vol. 2017.
@article{b93c265123e34b709f9a3eff7a381f7c,
title = "Intracardiac Hemostasis and Fibrinolysis Parameters in Patients with Atrial Fibrillation",
abstract = "Aims. To identify intracardiac hemostasis or fibrinolysis abnormalities, which are associated with atrial fibrillation (AF) and increase the risk of thromboembolism. Patients and Methods. Patient group consisted of 24 patients with AF and control group included 14 individuals with other supraventricular tachycardia undergoing transcatheter radiofrequency ablation. Blood samples were drawn from the femoral vein (FV), left atrium (LA), and left atrial appendage (LAA) before the ablation procedure. Fibrinogen, factor VIII (FVIII) and factor XIII activity, von Willebrand factor (VWF) antigen, thrombin-antithrombin (TAT) complex, quantitative fibrin monomer (FM), plasminogen, α2-plasmin inhibitor, plasmin-α2-antiplasmin (PAP) complex, PAI-1 activity, and D-dimer were measured from all samples. Results. Levels of FVIII and VWF were significantly elevated in the FV and LA of AF patients as compared to controls. TAT complex, FM, PAP complex, and D-dimer levels were significantly elevated in the LA as compared to FV samples in case of both groups, indicating a temporary thrombotic risk associated with the catheterization procedure. Conclusions. None of the investigated hemostasis or fibrinolysis parameters showed significant intracardiac alterations in AF patients as compared to non-AF controls. AF patients have elevated FVIII and VWF levels, most likely due to endothelial damage, presenting at both intracardiac and systemic level.",
author = "T{\'o}th, {No{\'e}mi Kl{\'a}ra} and Zolt{\'a}n Csan{\'a}di and Orsolya Hajas and Alexandra Kiss and Edina Nagy-Bal{\'o} and Kov{\'a}cs, {Kitti Bernadett} and Ferenc Sarkady and L. Muszbek and Z. Bereczky and L. Csiba and Z. Bagoly",
year = "2017",
month = "6",
day = "21",
doi = "10.1155/2017/3678017",
language = "English",
volume = "2017",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Intracardiac Hemostasis and Fibrinolysis Parameters in Patients with Atrial Fibrillation

AU - Tóth, Noémi Klára

AU - Csanádi, Zoltán

AU - Hajas, Orsolya

AU - Kiss, Alexandra

AU - Nagy-Baló, Edina

AU - Kovács, Kitti Bernadett

AU - Sarkady, Ferenc

AU - Muszbek, L.

AU - Bereczky, Z.

AU - Csiba, L.

AU - Bagoly, Z.

PY - 2017/6/21

Y1 - 2017/6/21

N2 - Aims. To identify intracardiac hemostasis or fibrinolysis abnormalities, which are associated with atrial fibrillation (AF) and increase the risk of thromboembolism. Patients and Methods. Patient group consisted of 24 patients with AF and control group included 14 individuals with other supraventricular tachycardia undergoing transcatheter radiofrequency ablation. Blood samples were drawn from the femoral vein (FV), left atrium (LA), and left atrial appendage (LAA) before the ablation procedure. Fibrinogen, factor VIII (FVIII) and factor XIII activity, von Willebrand factor (VWF) antigen, thrombin-antithrombin (TAT) complex, quantitative fibrin monomer (FM), plasminogen, α2-plasmin inhibitor, plasmin-α2-antiplasmin (PAP) complex, PAI-1 activity, and D-dimer were measured from all samples. Results. Levels of FVIII and VWF were significantly elevated in the FV and LA of AF patients as compared to controls. TAT complex, FM, PAP complex, and D-dimer levels were significantly elevated in the LA as compared to FV samples in case of both groups, indicating a temporary thrombotic risk associated with the catheterization procedure. Conclusions. None of the investigated hemostasis or fibrinolysis parameters showed significant intracardiac alterations in AF patients as compared to non-AF controls. AF patients have elevated FVIII and VWF levels, most likely due to endothelial damage, presenting at both intracardiac and systemic level.

AB - Aims. To identify intracardiac hemostasis or fibrinolysis abnormalities, which are associated with atrial fibrillation (AF) and increase the risk of thromboembolism. Patients and Methods. Patient group consisted of 24 patients with AF and control group included 14 individuals with other supraventricular tachycardia undergoing transcatheter radiofrequency ablation. Blood samples were drawn from the femoral vein (FV), left atrium (LA), and left atrial appendage (LAA) before the ablation procedure. Fibrinogen, factor VIII (FVIII) and factor XIII activity, von Willebrand factor (VWF) antigen, thrombin-antithrombin (TAT) complex, quantitative fibrin monomer (FM), plasminogen, α2-plasmin inhibitor, plasmin-α2-antiplasmin (PAP) complex, PAI-1 activity, and D-dimer were measured from all samples. Results. Levels of FVIII and VWF were significantly elevated in the FV and LA of AF patients as compared to controls. TAT complex, FM, PAP complex, and D-dimer levels were significantly elevated in the LA as compared to FV samples in case of both groups, indicating a temporary thrombotic risk associated with the catheterization procedure. Conclusions. None of the investigated hemostasis or fibrinolysis parameters showed significant intracardiac alterations in AF patients as compared to non-AF controls. AF patients have elevated FVIII and VWF levels, most likely due to endothelial damage, presenting at both intracardiac and systemic level.

UR - http://www.scopus.com/inward/record.url?scp=85021944760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021944760&partnerID=8YFLogxK

U2 - 10.1155/2017/3678017

DO - 10.1155/2017/3678017

M3 - Article

C2 - 28713823

AN - SCOPUS:85021944760

VL - 2017

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 3678017

ER -